The upregulation of fatty acid synthetase (FASN) is also frequent in KRAS-mutant cancer cells in order to provide a large amount of lipids, which are necessary to store energy and build cell membranes (116); indeed, FASN inhibitor TVB-2640 was tested (alone or in combination with a taxane) in a phase Ib trial in solid tumors including a cohort of pretreated NSCLC patients: a higher activity was seen in patients harboring a KRAS mutation, with a median time to progression of 22 weeks vs 5 weeks (p<0.02) (117). This evidence concerns the gene FASN and non-small cell lung carcinoma.